Factors associated with atomoxetine efficacy for treatment of attention-deficit/hyperactivity disorder in children and adolescents

Journal of Child and Adolescent Psychopharmacology

Volumn 20, Issue 3, 2010, Pages 197-203

  Scott, Nakia Gray ^a   Ripperger Suhler, Jane ^a   Rajab, M Hasan ^a   Kjar, Dean ^a  

^a TEXAS A AND M UNIVERSITY SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; ATOMOXETINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; METHYLPHENIDATE; ADRENERGIC RECEPTOR AFFECTING AGENT; CENTRAL STIMULANT AGENT; PROPYLAMINE;

ADOLESCENT; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; CHILD; COMORBIDITY; CONDUCT DISORDER; DEMOGRAPHY; DEPRESSION; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; ELECTRONIC MEDICAL RECORD; ENURESIS; FEMALE; HUMAN; LEARNING DISORDER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OPPOSITIONAL DEFIANT DISORDER; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SCHOOL CHILD; SUBSTANCE ABUSE; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ANXIETY; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; COMPLICATION; DRUG COMBINATION; PATHOPHYSIOLOGY;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ANXIETY; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD, PRESCHOOL; DEPRESSION; DRUG THERAPY, COMBINATION; ELECTRONIC HEALTH RECORDS; FEMALE; HUMANS; MALE; PROPYLAMINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77954940454     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2009.0104     Document Type: Article

References (27)

1. Agrawal S, Khan F: Human genetic variation and personalized medicine. Indian J Physiol Pharmacol 51:7-28, 2007. (Pubitemid 46424112)
2. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). Washington (DC): American Psychiatric Association, 1994.
3. Arnold LE; Aman MG, Cook AM, Witwer AN, Hall KL, Thompson S, Ramadan Y: Atomoxetine for hyperactivity in autism spectrum disorders: Placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry 45:1196-1205, 2006.
4. Atomoxetine ADHD and Comorbid MDD Study Group, Bangs ME, Emslie GJ, Spencer TJ, Ramsey JL, Carlson C, Bartky EJ, Busner J, Duesenberg DA, Harshawat P, Kaplan SL, Quintana H, Allen AJ, Sumner CR: Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression. J Child Adolesc Psychopharmacol 17:407-419, 2007.
5. Bangs ME, Hazell P, Danckaerts M, Hoare P, Coghill DR, Wehmeier PM, Williams DW, Moore RJ, Levine L; Atomoxetine ADHD/ODD Study Group: Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder. Pediatrics 121;e314-e320, 2008.
6. Bellgrove MA, Barry E, Johnson KA, Cox M, Daibhis A, Daly M, Hawi Z, Lambert D, Fitzgerald M, McNicholas F, Robertson IH, Gill M, Kirley A: Spatial attentional bias as a marker of genetic risk, symptom severity, and stimulant response in ADHD. Neu-ropsychopharmacology 33:2536-2545, 2008.
7. Biederman J, Spencer T, Newcorn JH, Gao H, Milton DR, Feldman PD, Witte MM: Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data. Psychopharmacol-ogy 190:31-41, 2007.
8. Brown TE: Atomoxetine and stimulants in combination for treatment of attention deficit hyperactivity disorder: Four case reports. J Child Adolesc Psychopharmacol 14:129-136, 2004.
9. Carlson GA, Dunn D, Kelsey D, Ruff D, Ball S, Ahrbecker L, Allen AJ: A pilot study for augmenting atomoxetine with methylpheni-date: Safety of concomitant therapy in children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health 1:10, 2007.
10. Carpenter LL, Milosavljevic N, Schecter JM, Tyrka AR, Price LH: Augmentation with open-label atomoxetine for partial or non-response to antidepressants. J Clin Psychiatry 66:1234-1238, 2005.
11. Cheng JYW, Chen RYL, Ko JSN, and Ng EML: Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis. Psychopharmacology 194:197-209, 2007.
12. Greenhill LL: Attention deficit-hyperactivity disorder: The stimulants. Child Adolesc Psychiatr Clin North Am 4:123-168, 1995.
13. Hammerness P, McCarthy K, Mancuso E, Gendron C, and Geller D: Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in chidren and adolescents: A review. Neuropsychiatric Dis Treat 5:215-226, 2009a.
14. Hammerness P, Georgiooulos A, Doyle RL, Utzinger L, Schillinger M, Martelon MK, Brodziak K, Biderman J, and Wilens TE: An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: II. Tolerability and pharmacokinetics. J Child Adolesc Psychopharmacol 19:493499, 2009b.
15. Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Saylor KE, Sutton VK, Gonzales J, Malcolm SK, Schuh KJ, Allen AJ: Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: A double blind, placebo-controlled trial. Pediatrics 114:e1-e8, 2004.
16. Kratochvil CJ, Newcorn JH, Arnold LE, Duesenberg D, Emslie GJ, Quintana H, Sarkis EH, Wagner KD, Gao H, Michelson D, Bie-derman J: Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry 44:915-924, 2005.
17. Michelson D, Buitelaar JK, Danckaerts M, Gillberg C, Spencer TJ, Zuddas A, Faries DE, Zhang S, Biederman J: Relapse prevention in pediatric patients with ADHD treated with atomoxetine: A randomized, double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 43:896-904, 2004.
18. Michelson D, Adler LA, Amsterdam JD, Dunner DL, Nierenberg AA, Reimherr FW, Schatzberg AF, Kelsey DK, Williams DW: Addition of Atomoxetine for depression incompletely responsive to sertra-line: A randomized, double-blind, placebo-controlled study. J Clin Psychiatry 68:582-587, 2007.
19. Newcorn JH, Spencer TJ, Biederman J, Milton DR, Michelson D: Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry 44:240-248, 2005.
20. Spencer TJ, Biederman J, Wilens TE, Faraone SV: Overview and neurobiology of attention-deficit/hyperactivity disorder. J Clin Psychiatry 63(suppl 12):3-9, 2002a.
21. Spencer TJ, Biederman J, Wilens TE, Faraone SV: Novel treatments for attention deficit-hyperactivity disorder in children. J Clin Psychiatry 63(suppl 12):16-22, 2002b.
22. Spencer TJ, Faraone SV, Michelson D, Adler LA, Reimberr FW, Glatt SJ, Biederman J: Atomoxetine and adult attention-deficit/hyperactivity disorder: The effects of comorbidity. J Clin Psychiatry 67:415-420, 2006.
23. Starr HL, Kemner J: Multicenter, randomized, open-label study of OROS methylphenidate vs. atomoxetine: Treatment outcomes in African American children with ADHD. J Natl Med Assoc 97(10 Suppl):11S-16S, 2005.
24. Sumner CR, Schuh KJ, Sutton VK, Lipetz R, Kelsey DK: Placebo-controlled study of the effects of atomoxetine on bladder control in children with nocturnal enuresis. J Child Adolesc Psychopharmacol 16:699-711, 2006.
25. Tasman A, Kay J, Lieberman J: Psychiatry Therapeutics, 2nd edition. West Sussex, England: John Wiley and Sons, Ltd., 2003.
26. Wilens TE, Biederman J, Spencer TJ, Prince J: Pharmacotherapy of adult attention deficit/hyperactivity disorder: A review. J Clin Psychopharmacol 15:270-279, 1995.
27. Wilens TE, Hammerness P, Utzinger L, Schillinger M, Georgiopou-lous A, Doyle R, Martelon MK, and Brodziak K: An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I. Effectiveness. J Child Adolesc Psychopharmacol 19:485-492, 2009.